CCL8

Across TCGA pan-cancer cohorts, CCL8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCL8 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CCL8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCL8 expression acts as an unfavorable survival marker.

ESCA, PAAD, and PRAD are the cancer types where CCL8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
PAAD	OS	Median	All	0.131	0.613	.001	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCL8–ESCA (OS)

Open the ESCA breakdown →